Evidence map›Paper›PMID 40706590›Full record

Trial reportCell reports. Medicine2025

IgA2

Daniel McCluskey, Muhammad R A Shipa, Kashfia Chowdhury, Judith A James, Laura A Cooney, Michael R Ehrenstein

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02260934 (Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02260934 phase2completednot on this map

Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2015 to 2019Enrolled43ConditionsLupus NephritisArmsRituximab, Cyclophosphamide, Prednisone, Methylprednisolone, Diphenhydramine
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel McCluskeyDepartment of Ageing, Rheumatology and Regenerative Medicine, University College London, London, UK.
Muhammad R A ShipaDepartment of Ageing, Rheumatology and Regenerative Medicine, University College London, London, UK.
Kashfia ChowdhuryComprehensive Clinical Trials Unit, University College London, London, UK.
Judith A JamesOklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Laura A CooneyImmune Tolerance Network, University of Michigan, Ann Arbor, MI, USA.
Michael R EhrensteinDepartment of Ageing, Rheumatology and Regenerative Medicine, University College London, London, UK. Electronic address: m.ehrenstein@ucl.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No theragnostic biomarkers exist for systemic lupus erythematosus (SLE) to enable a precision medicine approach. Baseline serum IgA2 anti-double-stranded DNA (dsDNA) antibody levels are associated with response to combination belimumab after rituximab therapy in SLE (BEAT-lupus trial, ISRCTN 47873003). Analysis of the CALIBRATE trial (NCT02260934) confirms that baseline IgA2 anti-dsDNA antibody levels are specifically associated with response to belimumab after rituximab (odds ratio [OR] = 16.9, confidence interval [CI]: 2.8-101, compared to rituximab alone-CALIBRATE and BEAT-lupus combined data). IgA2 anti-dsDNA antibody levels decrease alongside IgA2 expression in plasmablasts only after this combination treatment. Increased serum B cell-activating factor (BAFF) levels are associated with rising IgA2 anti-dsDNA antibody levels after rituximab. IgA2 plasmablasts have increased BAFF receptor and interleukin (IL)-10 expression compared to IgA1 plasmablasts and have a distinct integrin profile implicating a gut mucosal origin. These findings validate IgA2 anti-dsDNA antibodies as a theragnostic biomarker of response and provide mechanistic insight into the selective targeting of IgA2

Indexed as

Antibodies, AntinuclearAntibodies, Monoclonal, HumanizedB-LymphocytesImmunoglobulin ALupus Erythematosus, SystemicRituximabAdultB-Cell Activating FactorB-Cell Activation Factor ReceptorDNAFemaleHumansInterleukin-10MaleMiddle AgedAntibodies, AntinuclearAntibodies, Monoclonal, HumanizedB-Cell Activating FactorB-Cell Activation Factor ReceptorbelimumabDNAImmunoglobulin AInterleukin-10RituximabTNFSF13B protein, humanBAFFbelimumabCD11c(+)Tbet(+) age-related B cellsIgA2 anti-dsDNA antibodiesrituximabSLEtheragnostic biomarker

Identifiers

PMID40706590
PMCPMC12432362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.